Cardiovascular magnetic resonance feature tracking for characterization of patients with heart failure with preserved ejection fraction: correlation of global longitudinal strain with invasive diastolic functional indices

Haruno Ito 1, Masaki Ishida 1*, Wakana Makino 1, Yoshitaka Goto 1, Yasutaka Ichikawa 1, Kakuya Kitagawa 1, Taku Omori 2, Kaoru Dohi 2, Masaaki Ito 2 and Hajime Sakuma 1

Abstract

Background: Left ventricular (LV) diastolic dysfunction is the main cause of heart failure with preserved ejection fraction (HFpEF), and is characterized by LV stiffness and relaxation. Abnormal LV global longitudinal strain (GLS) is frequently observed in HFpEF, and was shown to be useful in identifying HFpEF patients at high risk for a cardiovascular event. Cardiovascular magnetic resonance (CMR) feature tracking (CMR-FT) enables the reproducible and non-invasive assessment of global strain from cine CMR images. However, the association between GLS and invasively measured parameters of diastolic function has not been investigated. We sought to determine the prevalence and severity of GLS impairment in patients with HFpEF by using CMR-FT, and to evaluate the correlation between GLS measured by CMR-FT and that measured by invasive diastolic functional indices.

Methods: Eighteen patients with HFpEF and 18 age- and sex-matched healthy control subjects were studied. All subjects underwent cine, pre- and post-contrast T1 mapping and late gadolinium-enhancement CMR. In the HFpEF patients, invasive pressure–volume loops were obtained to evaluate LV diastolic properties. GLS was quantified from cine CMR, and extracellular volume fraction (ECV) was quantified from pre- and post-contrast T1 mapping as a known imaging biomarker for predicting LV stiffness.

(Continued on next page)
Results: GLS was significantly impaired in patients with HFpEF (−14.8 ± 3.3 vs.−19.5 ± 2.8%, p < 0.001). Thirty nine percent (7/18) of HFpEF patients showed impaired GLS with a cut-off of −13.9%. Statistically significant difference was found in ECV between HFpEF patients and controls (32.2 ± 3.8% vs. 29.9 ± 2.6%, p = 0.044). In HFpEF patients, the time constant of active LV relaxation (Tau) was strongly correlated with GLS (r = 0.817, p < 0.001), global circumferential strain (GCS) (r = 0.539, p = 0.021) and global radial strain (GRS) (r = −0.552, p = 0.017). Multiple linear regression analysis revealed GLS as the only independent predictor of altered Tau (beta = 0.817, p < 0.001) among age, LV end-diastolic volume index, LV end-systolic volume index, LV mass index, GCS, GRS and GLS.

Conclusions: CMR-FT is a noninvasive approach that enables identification of the subgroup of HFpEF patients with impaired GLS. CMR LV GLS independently predicts abnormal invasive LV relaxation index Tau measurements in HFpEF patients. These findings suggest that feature-tracking CMR analysis in conjunction with ECV, may enable evaluation of diastolic dysfunction in patients with HFpEF.

Keywords: Cardiovascular magnetic resonance, Heart failure with preserved ejection fraction, Feature tracking, Global longitudinal strain, Extracellular volume fraction

Background
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and growing public health problem [1]. Although the pathophysiology of HFpEF is multifactorial, left ventricular (LV) diastolic dysfunction, which is characterized by LV stiffness and relaxation, is recognized as the main cause [2–4]. A previous study demonstrated that LV extracellular volume fraction (ECV) is a noninvasive indicator of LV stiffness in patients with HFpEF [5]. A more recent study employing speckle-tracking echocardiography found that systolic function measures such as LV global longitudinal strain (GLS) are frequently abnormal in HFpEF patients [6]. A recent study by Shah et al. also indicated that abnormal GLS is of value to identify patients with HFpEF at high risk for a cardiovascular event [7]. The cardiovascular magnetic resonance (CMR) feature tracking (FT; CMR-FT) technique enables the reproducible assessment of GLS from routine clinical CMR images with reduced observer dependency as compared to echocardiography [8]. However, the association between GLS determined by CMR-FT and the indices of diastolic function determined by cardiac catheterization has not been fully investigated in HFpEF patients. Consequently, the purposes of this study were to determine the prevalence and severity of GLS impairment in patients with HFpEF by using CMR-FT and to evaluate the relationship between CMR-FT GLS and diastolic functional indices determined by invasive catheterization.

Methods
Patient population
Twenty-eight patients with HFpEF who underwent invasive cardiac catheterization were enrolled. HFpEF was diagnosed in accordance with the following criteria: LV ejection fraction (EF) ≥50% as measured by echocardiography; New York Heart Association functional class ≥II; either E/e’ > 8 or average e’ < 9 cm/s on echocardiography, and plasma brain natriuretic peptide (BNP) level > 35 pg/mL [9, 10]. Exclusion criteria were coronary artery disease, acute coronary syndrome, prior myocardial infarction, greater than moderate valvular disease, hypertrophic obstructive cardiomyopathy, sarcoidosis, amyloidosis, persistent atrial fibrillation, general contraindication to CMR and an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m². The exclusion criteria are listed in Fig. 1. Consequently, 18 patients (65 ± 17 years; 3 males) with HFpEF who completed invasive catheterization and CMR were eligible. This population was compared with 18 age- and sex-matched healthy control subjects (61 ± 14 years; 7 males).

This study was conducted in accordance with the principles of the Declaration of Helsinki and with the approval of our Institutional Review Board (reference number 2742). All participants gave written, informed consent prior to participation in this study.

CMR imaging
CMR studies were performed on a 3 T CMR scanner (Ingenia, Philips Healthcare, Best, The Netherlands) using dS coils for signal reception. The CMR study protocol included cine CMR, native T1 mapping using a modified Look-Locker inversion recovery (MOLLI) sequence, late gadolinium enhancement (LGE) CMR and post-contrast T1 mapping using MOLLI. Cine CMR images were acquired with retrospective electrocardiographic gating and a segmented balanced steady-state free precession sequence during brief periods of breath-holding at a shallow expiration in the following planes: LV 2-chamber and 4-chamber views and short-axis planes covering the entire left ventricle and right ventricle (repetition time (TR), 3.2 ms; echo time (TE), 1.6 ms; flip angle (FA), 55°; field of view (FOV), 350 × 350 mm²; acquisition matrix, 176 × 306; reconstruction matrix, 352 × 352; slice thickness, 10 mm; sensitivity encoding (SENSE) factor, 3; temporal
resolution, 58 ± 11 ms; number of phases per cardiac cycle, 20) [11]. All cine images were acquired with 20 phases per cardiac cycle. The short-axis plane was defined as the plane perpendicular to the horizontal and vertical long-axis views. T1 mapping was performed using a 17-heartbeat steady-state free procession 3–3-5 MOLLI sequence on the short-axis imaging plane at the level of the LV base, midLV and apical levels (TR, 2.6 ms; TE, 1.1 ms; FA, 35°; FOV, 300 × 330 mm²; acquisition matrix, 176 × 141; reconstruction matrix, 288 × 288; slice thickness, 10 mm; SENSE factor, 2) [12]. At 5–10 min after bolus administration of gadoterate meglumine (Gd-DOTA, Magnescope®; Guerbet Japan, Tokyo, Japan) (cumulative dose of 0.15 mmL/kg), short- and long-axis 2D inversion recovery LGE images were acquired with an inversion recovery gradient-echo imaging sequence. Post-contrast MOLLI T1 mapping was repeated as for native T1 mapping [12].

**CMR image analysis**

CMR image analyses were carried out using CMR analysis software, cvi42 (Circle Cardiovascular Imaging Inc., Calgary, Canada) by an experienced radiologist (HI, 3 years of CMR experience) who was blinded to the subjects’ clinical information and the results of other diagnostic tests.

LV volume and function were analyzed based on the short-axis cine stack. The endocardial and epicardial borders of the LV wall were manually traced on cine CMR images in the end-diastolic and end-systolic phases. LV mass was calculated as the volume of the LV myocardium multiplied by the specific gravity of the myocardium (1.05 g/mL). Right ventricular (RV) volume and function were then analyzed based on the short-axis cine stack. LV and RV measurements were indexed to body surface area (BSA). To assess the time course of global volumetric filling, LV endocardial and epicardial contouring was added for all LV short-axis slices across all temporal phases. Peak filling rate (PFR) was defined as the maximal change in LV volume between sequential temporal phases (Δ volume/Δ phase) [13, 14]. This index was normalized for LV end-diastolic volume (nPFR) [15]. Left atrial (LA) volume was measured using the bi-plane area–length method, employing 2- and 4-chamber views [16]. Right atrial (RA) volume was measured using the single-plane area–length method in the 4-chamber view [17]. The maximal and minimal atrial volume was measured to calculate atrial ejection fraction.
LV and RV strain analysis was performed by a feature-tracking algorithm [18]. The endocardial and epicardial borders of myocardium were manually traced in the end-diastolic phase of 2- and 4-chamber view cine CMR images for LV GLS and a 4-chamber view cine CMR image for RV GLS. The software then automatically propagated the endocardial and epicardial contours and tracked the motion of the in-plane tissue voxels through the entire cardiac cycle. In addition, global circumferential strain (GCS) and global radial strain (GRS) was determined using short-axis cine CMR covering entire LV. Consequently, peak GLS, GCS and GRS were recorded for LV and peak GLS for RV [19]. LA myocardial feature tracking was performed, in which the LA endocardial and epicardial borders were manually traced in the 4-chamber view and an automated tracking algorithm was applied [20]. Tracking was repeated three times and the averages of these repetitions were used for further analyses [20].

T1 measurement was performed by pixel-wise quantification [12]. Respiratory motion in the images was corrected for by non-rigid image registration before T1 maps were generated by fitting pixels to the equation $s(t) = a - b \exp(-t/T1^*)$, and $T1 = T1^*(b/a-1)$, where $a$ and $b$ are constants, $t$ is time, and $s(t)$ is signal intensity at time $t$. The generated native and post-contrast T1 maps were stored in Digital Imaging and Communications in Medicine (DICOM) format. Native T1 values were averaged for the T1 value per pixel of the LV blood pool and the myocardium, determined on regions of interest manually drawn in the center of the blood pool and the LV myocardium, for each of the three LV short-axis images, before and after contrast administration. A pixel-wise extracellular volume fraction (ECV) map was then generated based on the combined pre- and post-contrast T1 maps using the formula: $ECV = (\Delta R1_{myocardium}/\Delta R1_{blood}) \times (1 – hematocrit)$, where $R1 = 1/T1$. ECV values were averaged for all pixels.

Cardiac catheterization protocol

Invasive cardiac catheterization was performed with right femoral artery access. To measure both LV volume and pressure simultaneously, a 6F single-field conductance catheter (Webster Laboratories, Baldwin Park, California, USA) with a 2F microtip manometer (Millar Instruments, Inc., Houston, Texas, USA) or a coronary-pressure guidewire (Phillips Volcano, CA, USA) placed within its lumen was advanced to the LV apex and connected to a digital stimulator microprocessor (Sigma V [dual-field system]; Leycom, Zoetermeer, The Netherlands). The conductance catheter technique and its principles have been fully described previously [21–23]. Calibration offset (parallel conductance) was corrected by matching the conductance catheter signal at end-diastole with the end-diastolic volume measured by cine CMR.

An experienced cardiologist without knowledge of other test results analyzed the conductance catheter data and invasive angiography data. The monoexponential-based time constant (Tau) of isovolumetric fall of LV pressure was calculated assuming that pressure decayed to a non-zero asymptote [24]. The diastolic pressure–volume relation is described by the exponential eq. $P = P0 + \alpha(e^{\beta V} - 1)$, where $P$ is LV pressure, $P0$ is pressure offset, $\alpha$ is a curve-fitting constant, $V$ is LV volume and $\beta$ is a load-independent constant used to quantify passive stiffness of the LV chamber [25].

Statistical analysis

Statistical analyses were performed using SPSS (v 19.0; Statistical Package for the Social Sciences, International Business Machines, Inc., Armonk, New York, USA). Normality of continuous variables was assessed using the Shapiro–Wilk test. As all continuous variables were normally distributed, data for continuous variables are presented as the mean ± standard deviation (SD). Categorical variables are presented as frequencies and percentages. Comparisons between groups were made using unpaired Student’s $t$ test for continuous variables and chi-square tests or Fisher exact test for categorical variables. Univariate and stepwise multivariate linear regression analyses were performed to identify predictors of Tau. Any variable with a $p$ value < 0.10 in a univariate analysis was included in a subsequent multivariable model. Pearson’s correlation coefficient was used to measure linear correlations between two variables. Statistical significance was defined as $p < 0.05$.

Results

The baseline characteristics of the 18 HFpEF patients and the 18 healthy control subjects are summarized in Table 1. HFpEF patients were more likely to have hypertension and diabetes compared with the control subjects. A more frequent use of antihypertensive and heart failure medications was noted in HFpEF patients compared with the controls.

CMR results

All 18 patients with HFpEF and the 18 healthy control subjects had complete CMR data. HFpEF patients had more impaired LV GLS (−14.8 ± 3.3% vs. −19.5 ± 2.8%, $p < 0.001$) (Fig. 2), GCS ($p = 0.004$) and GRS ($p = 0.007$). Thirty nine percent (7/18) of HFpEF patients showed impaired GLS with a cut-off of −13.9% (mean ± 2SD of controls). In addition as demonstrated in Table 2, HFpEF patients had a larger LV mass index ($p = 0.02$) and LV end-systolic volume index (ESVI; $p = 0.036$), more impaired LA total strain ($p = 0.042$), smaller LA EF ($p < 0.001$) and RA EF ($p = 0.001$), larger LA end-diastolic volume index (EDVI) ($p = 0.007$), LA ESVI; $p <
0.003), more impaired nPFR ($p < 0.001$) and higher ECV ($p = 0.044$). Representative cases are shown in Figs. 3 and 4.

**Correlation of measures of diastolic function**

The conductance catheter results are listed in Table 3. Tau and $\beta$ were $71.4 \pm 27.9$ ms and $0.051 \pm 0.011$, respectively.

Univariate linear regression analyses showed that, among age, CMR parameters and $\beta$, Tau was significantly correlated with age ($r = -0.676$, $p = 0.002$), LV EDVI ($r = 0.536$, $p = 0.022$), LV ESVI ($r = 0.486$, $p = 0.041$), LV mass index ($r = 0.504$, $p = 0.033$), LV GLS ($r = 0.817$, $p < 0.001$) (Fig. 5), LV GCS ($r = 0.539$, $p = 0.021$) and LV GRS ($r = -0.552$, $p = 0.017$) (Table 4). On step-wise multivariate linear regression analyses that included age, LV EDVI, LV ESVI, LV mass index, LV GRS, LV GCS and LV GLS as variables, LV GLS was the only independent predictor of Tau (beta $= 0.817$, $p < 0.001$).

**Discussion**

The main finding of this study is that among HFpEF patients CMR-FT GLS is independently associated with invasive measures of LV relaxation (Tau). Diastolic dysfunction is the hemodynamic consequence of the pathologies involved in HFpEF [5]. Prolongation of active myocardial relaxation and an increase in load-
endocardial dysfunction. Furthermore, GCS or GRS, suggesting that LV relaxation are closely
identified as a powerful prognostic factor in HFpEF patients [32]. Schuster et al. has shown that in the survi-
tient at high risk for cardiovascular morbidity and mortality [7], with a cut-off of \( \beta \) = 15.8%. CMR-
ECV by the CMR-only approach may provide two inde-
dependent parameters of LV relaxation and stiffness that may be the important pathomechanism in HFpEF pa-
tients too. The findings of our study support their hy-
pothesis. In our study, ECV value in controls was relatively high as compared to the previous studies. This might be because the mean age of controls was relatively high (61 ± 14 years) and 61% were female in which the ECV tends to demonstrate higher value.

In the present study, 39% of HFpEF patients showed impaired GLS with a value of less than \(-13.9\%\) (mean + 2SD of controls in our study). A recent study by Shah et al. using echocardiography reported impaired GLS as an independent imaging biomarker for identifying pa-
tients with HFpEF at high risk for cardiovascular mor-
ship. In our study, ECV value in controls was relatively high as compared to the previous studies. This might be because the mean age of controls was relatively high (61 ± 14 years) and 61% were female in which the ECV tends to demonstrate higher value.

In the present study, 39% of HFpEF patients showed impaired GLS with a value of less than \(-13.9\%\) (mean + 2SD of controls in our study). A recent study by Shah et al. using echocardiography reported impaired GLS as an independent imaging biomarker for identifying pa-
tients with HFpEF at high risk for cardiovascular mor-
borbidity and mortality [7], with a cut-off of \(-15.8\%\). CMR-
patients too. The findings of our study support their hy-
pothesis. In our study, ECV value in controls was relatively high as compared to the previous studies. This might be because the mean age of controls was relatively high (61 ± 14 years) and 61% were female in which the ECV tends to demonstrate higher value.

In the present study, 39% of HFpEF patients showed impaired GLS with a value of less than \(-13.9\%\) (mean + 2SD of controls in our study). A recent study by Shah et al. using echocardiography reported impaired GLS as an independent imaging biomarker for identifying pa-
tients with HFpEF at high risk for cardiovascular mor-
borbidity and mortality [7], with a cut-off of \(-15.8\%\). CMR-

### Table 2 Cardiovascular magnetic resonance data

|                          | HFpEF (n = 18) | Healthy Control (n = 18) | p-value |
|--------------------------|----------------|--------------------------|---------|
| LV EDV (mL/m²)           | 87.9 ± 21.3    | 79.1 ± 18.1              | 0.189   |
| LV ESV (mL/m²)           | 37.9 ± 13.9    | 29.6 ± 7.8               | 0.036   |
| LV EF (%)                | 57.6 ± 7.7     | 59.4 ± 14.4              | 0.646   |
| LV CI (L/min/m²)         | 3.27 ± 1.16    | 5.0 ± 8.21               | 0.381   |
| LV mass index (g/m²)     | 63.1 ± 30.7    | 43.9 ± 10.4              | 0.020   |
| LV ECV (%)               | 32.2 ± 3.8     | 29.9 ± 2.6               | 0.044   |
| LV GLS (%)               | −14.8 ± 3.3    | −19.5 ± 2.8              | <0.001  |
| LV GCS (%)               | −18.7 ± 4.2    | −22.5 ± 3.0              | 0.004   |
| LV GRS (%)               | 39.0 ± 14.6    | 50.9 ± 9.2               | 0.007   |
| nPFR                     | 1.82 ± 0.50    | 2.76 ± 0.77              | <0.001  |
| LA EDVI (mL/m²)          | 45.8 ± 15.7    | 33.1 ± 10.1              | 0.007   |
| LA ESVI (mL/m²)          | 25.7 ± 10.7    | 13.1 ± 5.4               | <0.001  |
| LA EF (%)                | 44.7 ± 6.5     | 60.9 ± 6.2               | <0.001  |
| LA total strain (%)      | 15.7 ± 5.1     | 18.9 ± 3.6               | 0.042   |
| LA conduit strain (%)    | 8.7 ± 4.0      | 10.3 ± 3.0               | 0.178   |
| RV EDVI (mL/m²)          | 66.6 ± 14.8    | 78.2 ± 19.6              | 0.052   |
| RV ESVI (mL/m²)          | 23.1 ± 9.1     | 30.1 ± 11.7              | 0.057   |
| RV EF (%)                | 65.5 ± 9.3     | 62.2 ± 9.4               | 0.301   |
| RV GLS (%)               | −20.9 ± 4.4    | −21.6 ± 4.4              | 0.643   |
| RA EDVI (mL/m²)          | 340.0 ± 12.7   | 285.3 ± 9.2              | 0.142   |
| RA ESVI (mL/m²)          | 210.0 ± 9.3    | 131.1 ± 4.5              | 0.003   |
| RA EF (%)                | 37.8 ± 13.6    | 52.9 ± 23.2              | 0.001   |

LV: Left ventricular; EDVI: End-diastolic volume index; ESV: End-systolic volume index; EF: Ejection fraction; CI: Cardiac index; ECV: Extracellular volume fraction; GLS: Global longitudinal strain; GCS: Global circumferential strain; GRS: Global radial strain; LA: Left atrial; RA: Right atrial; nPFR: Normalized peak filling rate
LA total strain might have incremental value for stratifying HFpEF patient prognosis, in addition to LV GLS and ECV. However, LA strain did not show the significant correlation with invasive measures of diastolic dysfunction in the current study and previous study [20], suggesting that LA strain parameters might offer exclusive clinical information which is only possible non-invasively. LA conduit function is closely related to LV stiffness [34]. von Roder et al. demonstrated that LA conduit strain was significantly impaired in HFpEF patients than controls and was the strongest predictor of exercise capacity [20]. However, in the present study, significant difference was not observed in LA conduit strain between HFpEF patients and control subjects. It might be speculated that LV stiffness in our patients was milder than the patients in the study by von Roder et al. Interestingly, Kowallick et al. demonstrated that LA conduit functions evaluated by CMR-FT can make discrimination among a hypertrophied phenotype, HFpEF and volunteers, as demonstrated by Mordi et al. where the discrimination between HFpEF and hypertensive heart disease was achieved based on GLS and ECV [35]. In the present study, there was no difference in RV volume or function between HFpEF patients and controls, whereas RA EF was significantly impaired in HFpEF patients compared with the controls. Recent study demonstrated that RV systolic function was preserved while RV early filling was impaired and compensated by increased RA booster pump function in compensated HFpEF patients [36]. Although it is difficult to interpret clinical implications of our finding at the present time, RV systolic function can be preserved with the impairment of RA function parameters in a certain condition. Future study focusing on RV and RA function in HFpEF patients is warranted.

The values of Tau and β in HFpEF patients were substantially different between our study and Rommel’s study. The reason for the difference may be due to the difference in the fitting equations to determine those values. In our study the best fit method assuming that pressure decayed to a non-zero asymptote was used for calculating Tau (P = P₀ e⁻ᵀau + P₉) [24], while Rommel et al. employed Weiss’s method (P = e⁻βV) (asymptote = 0) [37]. To determine β, the formula of “P = A eβV” was used in Rommel’s study [38], whereas the formula of “P = A (eβV - 1)” was used in the present study [25], where P is the LV pressure, V is the LV volume, A is a curve fitting constant. Consequently, our method provide larger Tau and smaller β compared to Rommel’s method. LV pressure volume analysis has remained a more research-based reference standard for confirming definite evidence of HFpEF due to its invasive nature. The
pulmonary wedge pressure (PCWP) during physiological exercise emerged as the clinical reference standard to define HFrEF [39], which is clinically beneficial as it can avoid the risk of conventional LV pressure volume analysis. However, the study investigating the association between exercise PCWP and CMR functional parameters is still lacking. Further study will be needed.

In our study, cine images consisted of 20 phases per cardiac cycle. Cine images with lower temporal resolution are more prone to miss the short-lived events during the isovolumic period. However, longer breath-hold duration is required to obtain higher temporal resolution in cine CMR imaging. In this respect, typically cine CMR with 20–30 phases per cardiac cycle was used in the most of previous studies [15, 18, 20, 40, 41]. CMR-FT using cine images consisting of 20–30 phases per cardiac cycle substantially underestimated true GLS [42]. However, the previous studies and our study successfully demonstrated that cine images with 20–30 phases per cardiac cycle can provide useful information in a clinical setting [15, 18, 20, 40, 41].

Echocardiography enables the noninvasive identification of diastolic dysfunction based on transmitral inflow (E and A values) or on myocardial compliance sampled at regional myocardial locations (e′) [43]. The global LV filling curves of cine CMR provide an alternative means of assessing diastolic physiology based on the timing and pattern of dynamic changes in LV chamber volume [13, 14]. The LV filling curve is usually transformed to the first derivative to obtain the early filling profile (i.e., PFR), which corresponds to the E value measured by echocardiography. Because it is influenced by filling pressure as well as inversely altered by changes in relaxation [26], E is usually corrected for the influence of

Table 3 Conductance catheter data

| HFpEF (n = 18) | HR, beats/min | 66.6 ± 7.8 |
| HR, beats/min | LV ESP, mmHg | 148.9 ± 34.4 |
| LV ESP, mmHg | LV EDP, mmHg | 15.2 ± 8.3 |
| LV EDP, mmHg | Tau, ms | 71.4 ± 27.9 |
| Tau, ms | LV ESPVR, mmHg/mL | 2.0 ± 1.3 |
| LV ESPVR, mmHg/mL | Ea, mmHg/mL | 2.1 ± 1.0 |
| Ea, mmHg/mL | β | 0.051 ± 0.011 |

HR Heart rate, ESP End-systolic pressure, EDP End-diastolic pressure, ESPVR End-systolic pressure–volume relationship, Ea Arterial elastance
Table 4 Correlation of various factors with the time constant of active relaxation (Tau)

| Factor                  | Pearson’s correlation coefficient (r) | B non-standardized | p   |
|-------------------------|--------------------------------------|-------------------|-----|
| Age                     | −0.676                               | −1.118            | 0.002|
| BMI                     | 0.102                                | 0.424             | 0.687|
| LV EDVI                 | 0.536                                | 0.703             | 0.022|
| LV ESVI                 | 0.486                                | 0.978             | 0.041|
| LV CI                   | 0.067                                | 1.622             | 0.791|
| LV EF                   | −0.244                               | −88.398           | 0.328|
| LV mass index           | 0.504                                | 0.458             | 0.033|
| LV ECV                  | −0.064                               | −0.467            | 0.801|
| LV GLS                  | 0.817                                | 6.141             | <0.001|
| LV GCS                  | 0.539                                | −3.795            | 0.021|
| LV GRS                  | −0.352                               | −1.411            | 0.017|
| nPFR                    | −0.015                               | −0.845            | 0.953|
| LA EDVI                 | 0.219                                | 0.390             | 0.383|
| LA ESVI                 | 0.141                                | 0.367             | 0.577|
| LA EF                   | 0.068                                | 29.204            | 0.788|
| LA total strain         | −0.061                               | −0.339            | 0.816|
| LA conduit strain       | 0.195                                | 1.382             | 0.452|
| RV EDVI                 | 0.36                                 | 0.679             | 0.142|
| RV ESVI                 | 0.104                                | 0.320             | 0.683|
| RV EF                   | 0.234                                | 70.330            | 0.351|
| RV GLS                  | 0.412                                | 2.639             | 0.089|
| RA EDVI                 | −0.169                               | −0.372            | 0.504|
| RA ESVI                 | −0.124                               | −0.371            | 0.625|
| RA EF                   | −0.106                               | −21.681           | 0.676|
| β                       | 0.106                                | 226.886           | 0.686|

Univariate regression analysis was performed with the Pearson correlation coefficient.
relaxation (e’) in echocardiography (E/e’). In agreement with previous studies, in the present study PFR normalized by LV end-diastolic volume (nPFR) was significantly impaired in HFP EF patients compared with controls [13, 14]. However, the present study found no association of PFR or nPFR with Tau, which can be attributed to the load dependence of global LV filling curves. Abnormalities observed in the global LV filling curve may be less specific to the pathomechanism of diastolic dysfunction in the individuals with HFP EF when compared to GLS and Tau.

Study limitations
Several limitations should be acknowledged in our study. First, the number of participants was relatively small. Small patient populations due to restrictive inclusion and exclusion criteria can lead to a narrow spectrum of myocardial conditions. Second, LA strain was only assessed from the 4-chamber view. Generally, 4-chamber view is susceptible to the accuracy of the breath-hold. However, the status of the breath-hold was highly stable in all HFP EF patients. The image quality of LA in the 2-chamber view cine CMR images was suboptimal in 7 patients with HFP EF (38.9%) in our study. Therefore, we used only the 4-chamber cine CMR to obtain LA strain.

Conclusions
CMR-FT is a noninvasive approach that enables identification of the subgroup of HFP EF patients who have impaired LV GLS, and LV GLS assessed by this technique independently predicts abnormal LV relaxation measured by invasive conductance catheter in HFP EF patients. Diastolic dysfunction can be evaluated noninvasively in patients with HFP EF via the CMR approach using LV GLS in conjunction with ECV, which was previously shown to be an imaging biomarker for predicting LV stiffness.

Abbreviations
BNP: Brain natriuretic peptide; BSA: Body surface area; CAD: Coronary artery disease; CMR: Cardiovascular magnetic resonance; CMR-FT: Cardiovascular magnetic resonance feature tracking; Dicom: Digital Imaging and Communications in Medicine; Ea: Arterial elastance; ECV: Extracellular volume fraction; EDP: End-diastolic pressure; EDV: End-diastolic volume index; EF: Ejection fraction; eGFR: Estimated glomerular filtration rate; ESP: End-systolic pressure; ESPVR: End-systolic pressure-volume relationship; ESV: End-systolic volume index; FA: Flip angle; FOV: Field of view; FT: Feature tracking; GCS: Global circumferential strain; Gd-DOTA: Gadodeterate meglumine; GLS: Global longitudinal strain; GRS: Global radial strain; HFP EF: Heart failure with preserved ejection fraction; HR: Heart rate; LA: Left atrium/left atrial; LGE: Late gadolinium enhancement; LVEF: Left ventricular ejection fraction; MOLLI: Modified Look-Locker inversion recovery; nPFR: PFR normalized by LV end-diastolic volume; PCWP: Pulmonary wedge pressure; PFR: Peak filling rate; RA: Right atrium/right atrial; RV: Right ventricle/right ventricular; SD: Standard deviation; SENSE: Sensitivity encoding; TE: Echo time; TR: Repetition time

Acknowledgements
The authors would like to thank Shinichi Takase (MR technologist, Mie University Hospital) for performing all CMR image acquisition and for providing technical support regarding this study.

Authors’ contributions
HI participated in study design, scored the studies, conducted the statistical analysis, interpreted the data, and drafted the manuscript. MI participated in study design, scored the studies, interpreted the data, and revised the manuscript. YG and WM scored the studies and interpreted the data. YI and KK scored the studies. TO participated in study design, scored the studies and interpreted the data. KD participated in study design, scored the studies and interpreted the data. MI and HS participated in study design and revised the manuscript. The authors have read and approved the final manuscript.

Funding
This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study was conducted in accordance with the principles of the Declaration of Helsinki and with the approval of the Mie University Institutional Review Board at Mie University Hospital (No. 2742, June 16th, 2014). All participants gave their written, informed consent prior to participation in this study. No studies involving animals were performed.

Consent for publication
Written, informed consent was obtained from the patients for publication of their individual details and accompanying images in this manuscript. Consent forms are held by the authors/the authors’ institution and are available for review by the Editor-in-Chief.

Competing interests
Hajime Sakuma, MD receives departmental research grant support from Daiichi Sankyo Company Limited, FUJIFILM Holdings Corporation, Nihon Medi-Physics Co., Ltd., Bayer AG, Siemens AG, Fuji Pharma Co., Ltd., Guerbet SA, and Eisai Co., Ltd. Masaaki Ito, MD receives departmental research grant support from Bristol-Myers Squibb, MSD KK, Shionogi & Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited and Dai-ichi, Sankyo Company Limited. All other authors have no conflicts of interest to declare. No relevant conflicts of interest related to the article are disclosed by the authors.

Author details
1 Departments of Radiology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. 2 Departments of Cardiology and Nephrology, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.

Received: 19 August 2019 Accepted: 8 May 2020

References
1. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Get with the guidelines scientific advisory committee and investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(6):75–75.
2. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(18):1866–77.
3. Zile MR, Bairen CF, Gaasch WH. Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–9.
4. Westermann D, Kasner M, Steendijk P, Spillmann F, Ried A, Weitmann K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117:2051–60.
5. Rammel KP, von Roeder M, Latusczyński K, Oberueck C, Blazek S, Fengler K, et al. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2016;67:1815–25.
6. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63:447–56.
7. Shah AM, Claggatt B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132:402–14.

8. Pedazzetti G, Claus P, Kliner PJ, Nagel E. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J Cardiovasc Magn Reson. 2016;18:51.

9. Okada S, Yano M. Guidelines for treatment of chronic heart failure (JCS 2010). Nihon Rinsho. 2011;69:595–604.

10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJ, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Rev Esp Cardiol (Engl Ed). 2016;69:167.

11. Motwani K, Takeuchi T, Fujimoto N, Sawa T, Sato Y, Kumagai N, et al. Effect of Sitaglipitin on coronary flow reserve assessed by magnetic resonance imaging in type 2 diabetic patients with coronary artery disease. Circ J. 2018;82:2119–27.

12. Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T, et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovascular Imaging. 2018;11:148–59.

13. Kawaji K, Codella NC, Prince MR, Chu CW, Shakoor A, LaBounty TM, et al. Automated segmentation of routine clinical cardiac magnetic resonance imaging for assessment of left ventricular diastolic dysfunction. Circ Cardiovasc Imaging. 2009;2:476–84.

14. Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFrEF. JACC Cardiovascular Imaging. 2014;7:991–7.

15. Wei J, Mehta PK, Shufelt C, Yang Y, Gill E, Kahlon R, et al. Diastolic dysfunction measured by cardiac magnetic resonance imaging in women with signs and symptoms of ischemia but no obstructive coronary artery disease. Int J Cardiol. 2016;220:775–80.

16. Zemrak F, Ambale-Venkatesh B, Captur G, Chrispin J, Chamera E, Habibi M, et al. Left atrial structure in relationship to age, sex, ethnicity, and cardiovascular risk factors: MESA (multi-ethnic study of atherosclerosis). Circ Cardiovasc Imaging. 2017;10.

17. Tsoo CW, Josephson ME, Hauser TH, Halloran TDD, Agarwal A, Manning WJ, et al. Accuracy of electrocardiographic criteria for atrial enlargement: validation with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:3.

18. Goto Y, Ishida M, Takase S, Sigfridsson A, Uno M, Nagata M, et al. Comparison of displacement encoding with stimulated echoes to magnetic resonance feature tracking for the assessment of myocardial strain in patients with acute myocardial infarction. Am J Cardiol. 2017;119:1542–7.

19. Park J-H, Negishi K, Kwon DH, Popovic ZB, Grimm RA, Marwick TH, et al. Validation of global longitudinal strain and strain rate as reliable markers of right ventricular dysfunction: comparison with cardiac magnetic resonance and outcome. J Cardiovasc Ultrasound. 2014;22:113–20.

20. von Roeder M, Rommel KP, Kowallick JT, Blazek S, Besler C, Fengler K, et al. Right atrial-right ventricular coupling in heart failure with preserved ejection fraction. Clin Res Cardiol. 2019;109:54–66.

21. Jorde BJ. Left atrial size and function: role in prognosis. J Am Coll Cardiol. 2014;63:493–505.

22. Kowallick JT, Kutty S, Edvardsen T, Steinmetz M, et al. Quantification of left atrial strain and strain rate using cardiovascular magnetic resonance myocardial feature tracking: a feasibility study. J Cardiovasc Magn Reson. 2014;16:60.

23. von Roeder M, Kowallick JT, Rommel KP, Blazek S, Besler C, Fengler K, et al. Right atrial-right ventricular coupling in heart failure with preserved ejection fraction. Eur Heart J. 2019;40:3297–302.

24. Lee JM. Accurate atrial feature tracking in patients with heart failure with preserved ejection fraction. Circulation. 2019;139;2852–62.

25. Mordi IR, Singh S, Rudd A, Srivinasan J, Frenneaux M, Tzemos N, et al. Comprehensive echocardiographic and cardiac magnetic resonance evaluation differentiates among heart failure with preserved ejection fraction patients, hypertensive patients, and healthy control subjects. JACC Cardiovascular Imaging. 2018;11:577–85.

26. Rosca M, Lancellotti P, Popescu BA, Pielard LA. Left atrial function: pathophysiology, echocardiographic assessment, and clinical applications. Heart. 2011;97:1982–9.

27. Santos AB, Rosca GQ, Claggatt B, Sweitzer NK, Shah SJ, Anand IS, et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9:e002763.

28. Schuster A, Backhaus SJ, Steinauer T, Navarra JL, Uhlig J, Rommel KP, et al. Left atrial strain with MRI enables prediction of cardiovascular events after myocardial infarction: insights from the AIDA STEMi and TATORT nSTEMI trials. Radiology. 2019;293:292–302.

29. Holt BD. Left atrial size and volume: role in prognosis. J Am Coll Cardiol. 2014;63:493–505.

30. Mordi IR, Singh S, Rudd A, Srivinasan J, Frenneaux M, Tzemos N, et al. Comprehensive echocardiographic and cardiac magnetic resonance evaluation differentiates among heart failure with preserved ejection fraction patients, hypertensive patients, and healthy control subjects. JACC Cardiovascular Imaging. 2018;11:577–85.

31. Rosca M, Lancellotti P, Popescu BA, Pielard LA. Left atrial function: pathophysiology, echocardiographic assessment, and clinical applications. Heart. 2011;97:1982–9.

32. Santos AB, Rosca GQ, Claggatt B, Sweitzer NK, Shah SJ, Anand IS, et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9:e002763.

33. Schuster A, Backhaus SJ, Steinauer T, Navarra JL, Uhlig J, Rommel KP, et al. Left atrial strain with MRI enables prediction of cardiovascular events after myocardial infarction: insights from the AIDA STEMi and TATORT nSTEMI trials. Radiology. 2019;293:292–302.

34. Holt BD. Left atrial size and volume: role in prognosis. J Am Coll Cardiol. 2014;63:493–505.

35. Kowallick JT, Kutty S, Edvardsen T, Steinmetz M, et al. Quantification of left atrial strain and strain rate using cardiovascular magnetic resonance myocardial feature tracking: a feasibility study. J Cardiovasc Magn Reson. 2014;16:60.

36. von Roeder M, Kowallick JT, Rommel KP, Blazek S, Besler C, Fengler K, et al. Right atrial-right ventricular coupling in heart failure with preserved ejection fraction. Clin Res Cardiol. 2019;109:54–66.

37. Minkis I. Assessment of diastolic function: suggested methods and future considerations. Circulation. 1984;69:386–41.

38. Burkhoff D, Minkis I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:H501–12.

39. Piekje B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PeFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297–317.

40. Kleijn SA, Brouwer WP, Aly MF, Rüssel IK, de Roest GJ, Beek AM, et al. Right atrial-tight ventricular coupling in heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging. 2012;13:834–9.

41. Wu L, Germans T, Güdüz A, Heymans MW, Allaart CP, van Rossum AC. Feature tracking compared with tissue tagging measurements of segmental strain by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:10.

42. Amzulescu MS, De Craene M, Langet H, Pasquet A, Vancraeynest D, Pouleur AC, et al. Myocardial strain imaging: review of general principles, validation, and sources of discrepancies. Eur Heart J Cardiovasc Imaging. 2019;20:605–19.

43. Naghieh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.